OSE Immuno receives new recommendation for lung cancer trial

OSE Immunotherapeutics has received a second positive recommendation from the independent Data Monitoring Committee (IDMC) for its Phase 3 ARTEMIA trial.

The trial is evaluating the efficacy of Tedopi® in patients diagnosed with non-small cell lung cancer. The IDMC's recommendation allows the study to continue as planned, based on an analysis of the data collected to date.

The ARTEMIA trial is currently underway in multiple countries and involves patients who have not previously received treatment. Tedopi® is an immunotherapy developed to activate the body's immune system to fight cancer cells.

OSE Immunotherapeutics will continue to gather and analyze data throughout the study. The company plans to announce further results once the clinical endpoints are met.